Intrexon | XON - Assets


Intrexon reported $73.16M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
Agenus USD 226.8M 7.09M Dec/2025
Alaunos Therapeutics USD 2.97M 758K Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Incyte USD 7.34B 381.14M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
MannKind USD 792.18M 297.54M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Veracyte USD 1.41B 38.23M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025